NCT01702896

Interleukin-2 in Metastatic Melanoma

Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Melanoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Western Regional Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage

Detailed description

In this phase II trial, the previously described IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks) will be tested in a larger cohort of patients with melanoma to attempt to determine the response rate, median duration of response, and median survival. The dose intensity of this schedule would allow a patient treated on this regimen to achieve the target threshold (\> 1440 million IU/m2/year).

Conditions

• Melanoma Metastatic

Interventions

Type	Name	Description
DRUG	Interleukin-2	Interleukin-2

Timeline

• Start date: 2012-09-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2012-10-10
• Last updated: 2018-04-05
• Results posted: 2018-02-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study